文献速递临床试验与 GCP流行病学与生物统计

二元结局的贝叶斯剂量选择设计:采用限制性反应适应性随机化

Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
PubMed 文献 · Trials · 2017-09-08

针对II期试验中最优剂量未知且资源有限的问题,提出一种安慰剂对照的贝叶斯反应适应性随机化(RAR)设计,将多数受试者分配至最优剂量,同时固定活性药与安慰剂的比例以保留检验效能。以蛛网膜下腔出血II期试验为例展示设计特性与优化,发现固定样本量下最优剂量选择能力与拒绝原假设概率存在权衡,且受分配比、RAR算法和初始固定分配期样本数影响。

要点

  • 限制性贝叶斯反应适应性随机化将多数受试者分配至最优剂量,同时保持活性药与安慰剂分配比恒定以保留检验效能。
  • 固定总样本量下,最优剂量选择能力与拒绝原假设概率之间存在权衡。
  • 响应性RAR算法提高正确剂量选择能力,但可能因数据短暂趋势将更多受试者分配至较差组。

核心结论

  • 贝叶斯适应性设计是在有限资源下灵活解决围绕最佳疗效剂量多个问题的途径。
  • 该设计通用性足以适用于许多情况,但未来工作需要解决期中分析和纳入剂量反应模型。

研究设计与样本

  • 提出一种安慰剂对照设计,采用限制性贝叶斯反应适应性随机化(RAR)分配受试者,以蛛网膜下腔出血II期试验为背景展示设计特性与优化。

主要发现

  • 固定总样本量下,最优剂量选择能力与拒绝原假设的概率之间存在权衡。
  • 该权衡关系受活性药与对照受试者分配比、RAR算法选择以及初始固定分配期受试者数量的影响。
  • 响应性RAR算法提高正确剂量选择能力,但存在因数据短暂趋势将更多受试者分配至较差组的风险增加。

局限性

  • 未来工作需要解决期中分析和纳入剂量反应模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In phase II trials, the most efficacious dose is usually not known. Moreover, given limited resources, it is difficult to robustly identify a dose while also testing for a signal of efficacy that would support a phase III trial. Recent designs have sought to be more efficient by exploring multiple doses through the use of adaptive strategies. However, the added flexibility may potentially increase the risk of making incorrect assumptions and reduce the total amount of information available across the dose range as a function of imbalanced sample size. METHODS: To balance these challenges, a novel placebo-controlled design is presented in which a restricted Bayesian response adaptive randomization (RAR) is used to allocate a majority of subjects to the optimal dose of active drug, defined as the dose with the lowest probability of poor outcome. However, the allocation between subjects who receive active drug or placebo is held constant to retain the maximum possible power for a hypothesis test of overall efficacy comparing the optimal dose to placebo. The design properties and optimization of the design are presented in the context of a phase II trial for subarachnoid hemorrhage. RESULTS: For a fixed total sample size, a trade-off exists between the ability to select the optimal dose and the probability of rejecting the null hypothesis. This relationship is modified by the allocation ratio between active and control subjects, the choice of RAR algorithm, and the number of subjects allocated to an initial fixed allocation period. While a responsive RAR algorithm improves the ability to select the correct dose, there is an increased risk of assigning more subjects to a worse arm as a function of ephemeral trends in the data. A subarachnoid treatment trial is used to illustrate how this design can be customized for specific objectives and available data. CONCLUSIONS: Bayesian adaptive designs are a flexible approach to addressing multiple questions surrounding the optimal dose for treatment efficacy within the context of limited resources. While the design is general enough to apply to many situations, future work is needed to address interim analyses and the incorporation of models for dose response.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Meinzer C, Martin R, Suarez JI, et al. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization. Trials. 2017. PMID: 28886745. doi:10.1186/s13063-017-2004-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。